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Reversal of Severe Osteoporosis With Vitamin B 12 and Etidronate Therapy in a 
Patient With Pernicious Anemia 
Mary E. Melton and Michael L. Kochman 
Pernicious anemia has recently been recognized as a risk factor for osteoporosis and fractures. Although vitamin B12 is 
important for osteoblast function, the effect of vitamin B,z replacement in states of vitamin 8,~ deficiency on bone density and 
fracture incidence is not known. We report 2-year follow-up data from a patient with severe osteoporosis, multiple vertebral 
compression fractures, and pernicious anemia who exhibited a dramatic response to treatment with vitamin B12 and cyclic 
etidronate. Serial bone density measurements demonstrated a 15% and 17% increase in the lumbar and greater trochanter 
regions, respectively, and a 79% increase in the femoral neck region over the 2-year follow-up period. In addition to 
normalization of bone density compared with age-matched controls, no subsequent vertebral fractures were noted in the 
2-year period following initiation of vitamin B12 and etidronate therapy. This case demonstrates that osteoporosis associated 
with pernicious anemia may be markedly improved by vitamin 8,~ replacement and cyclic etidronate therapy. 
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P ERNICIOUS ANEMIA has been identified as a risk factor for osteoporosis* and proximal femur, distal 
forearm, and vertebral fractures.? Vitamin Blz is thought to 
be important for osteoblast activity. and treatment of 
pernicious anemia with vitamin Blz increases serum mark- 
ers of bone formation? However, the effect of vitamin B12 
replacement on bone density and fracture rate over time in 
patients with pernicious anemia and osteoporosis has not 
been studied. Bisphosphonates administered in a cyclic 
regimen have been used with success to treat postmeno- 
pausal osteoporosis; i,5 however, their efficacy in treating 
osteoporosis due to other causes is not known. Here we 
report data from a 2-year observation period of a man with 
pernicious anemia accompanied by severe osteoporosis and 
multiple vertebral fractures in whom marked improvement 
in bone density and reduction in fracture incidence oc- 
curred while undergoing treatment with vitamin B12 and 
cyclic etidronate. 
CASE REPORT 
A 6%year-old man presented with a ‘-year history of multiple 
thoracic and lumbar vertebral compression fractures. He had 
initially sought medical attention for an episode of thoracic back 
pain. Evaluation by his local physician revealed compression 
fractures of the eighth and ninth thoracic vertebrae, with normal- 
appearing lumbar vertebrae. A subsequent episode of acute back 
pain revealed mild compression fractures of the first and second 
lumbar vertebrae. Salmon calcitonin therapy was initiated, but 
moderate compression fractures of both the fifth and eleventh 
thoracic vertebrae developed. Upon presentation to our clinic, he 
had been receiving subcutaneous salmon calcitonin 100 IU daily 
for the previous 7 months, as well as 1,666 mg elemental calcium 
and 667 IU vitamin D daily for 2 years. 
Screening studies for etiologies of osteoporosis were performed. 
Serum electrolytes, calcium, phosphorus. alkaline phosphatase. 
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folate, testosterone, thyroid-stimulating hormone, parathyroid hor- 
mone. and protein electrophoresis were normal. The hemoglobin 
level was 7.7 mmol/L (12.4 g/dL). The hematocrit value was 36.5% 
with a mean cell volume of 101 pm~icell. The red blood cell count 
was 3.5 x 10h/mm’. and the white blood cell count was 5.200/mmz. 
The serum vitamin B,? level was low at 116 pmol/L (157 pg/mL; 
normal > 200 pg/mL). Small-bowel mucosal biopsies were nor- 
mal. A Schilling test was consistent with the diagnosis of pernicious 
anemia, ie. a first-phase excretion of 5.2% in 24 hours (nor- 
mal > 8.0%) and a second-phase (with intrinsic factor) excretion 
of 13.1% in 24 hours. A parietal cell antibody titer was positive at a 
1:20 dilution. 
Bone density measurements obtained by dual-photon absorpti- 
ometry ([DPA] Lunar DP3. Madison. WI) confirmed the presence 
of osteopenia in the lumbar spine and proximal femur (Table I). 
The lumbar spine density may have been overestimated due to the 
presence of compression fractures in this area. 
Treatment was initiated with monthly intramuscular injections 
of vitamin B,:. In addition, a course of cyclic etidronate therapy 
consisting of 400 mg orally per day for the first 2 weeks of every 3 
months was prescribed: 1,500 mg elemental calcium and 400 IU 
vitamin D were administered daily throughout the treatment 
period. No new episodes of back pain occurred. No subsequent 
vertebral compression fractures were noted on follow-up spine 
films at 2 years. The serum vitamin B1: level increased to 295 
pmol/L (400 pg/mL). The anemia improved, and the mean cell 
volume decreased to 96 ~m”/cell. 
Follow-up bone density measurements were obtained using 
dual-energy x-ray absorptiometry ([DEXA] Lunar DPX) after 2 
years of treatment (Table 1). The bone density in both the lumbar 
spine and proximal femur had increased markedly and was normal 
for age. 
DISCUSSION 
There are no published reports describing the effect on 
bone disease of vitamin B,l replacement or other therapies 
in patients with osteoporosis due to pernicious anemia or 
other causes of vitamin B13 deficiency. This patient dis- 
played a marked improvement in bone density with the 
combination of vitamin B,z and cyclic ctidronate therapy. 
The comparison of bone density measurements must be 
interpreted with an understanding of the different densitom- 
etry systems. A comparison of the two densitomctry tech- 
niques used in this report (DPA and DEXA, Lunar) at both 
lumbar vertebrae and the femoral neck has shown a high 
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Table 1. Bone Density Measurements Initially and Following 2 Years 
of Therapy With Vitamin Bj2 and Etidronate 
% 
Initial+ 2 Yearst Change* 
Lumbar vertebrae 2-4 
Bone density (g/cm? 1.097 1.254 +15 
Compared with young normal (%) 87.0 101 
Compared with age-matched (%) 88.1 103 
Femoral neck 
Bone density (g/cmZ) .51 ,912 +79 
Compared with young normal (%I 50.7 88 
Compared with age-matched 1%) 56.3 103 
Greater trochanter 
Bone density (g/cmZ) .64 ,751 +17 
Compared with young normal (%) 79.5 83 
Compared with age-matched (%) 79.7 89 
*Initial bone density measurements were performed using DPA 
(Lunar DP3 system). 
tTwo-year follow-up measurements were obtained using DEXA 
(Lunar DPX system). 
etidronate, it is unclear whether a single agent or a 
combination of agents acting synergistically was responsible 
for the reversal of osteoporosis. Etidronate is thought to act 
primarily by decreasing bone resorption. Cyclic administra- 
tion of etidronate has been associated with modest in- 
creases in bone density in patients with postmenopausal 
osteoporosis.4J Dramatic increases in bone mineral density, 
as seen in this patient, have not been reported as a result of 
etidronate therapy alone. Vitamin B12 appears to be impor- 
tant for osteoblast activity and bone formation3 Whether 
vitamin Blz alone could be responsible for the improvement 
seen in this patient is unknown. Theoretically, by adminis- 
tering these two agents simultaneously, the rate of bone 
resorption would be decreased by etidronate while at the 
same time vitamin B12 replacement would allow bone 
formation to proceed, resulting in a net increase in bone 
density above what might be expected from vitamin B,? 
alone. 
SDPX ‘data were compared with DP3 data at L2-4 by applying the 
following equation: DPX = 1.072 DP3 - 0.095.6 
correlation (r > .97).h In fact, the DEXA measurements 
tend to be slightly lower than the DPA measurements6 
Taking this into account, the increase in bone density seen 
in this patient was more likely to have been underestimated 
rather than overestimated. Therefore, it is not possible to 
explain the improvement in bone density in this patient by 
differences in densitometry technique. Indeed, it is most 
likely that the therapy instituted in this patient was respon- 
sible for the dramatic improvement in bone density. 
Since this patient received both vitamin B12 and cyclic 
The dramatic improvement seen in this patient suggests 
that osteoporosis due to vitamin B12 deficiency may be 
reversible and easily treated. Vitamin Bt2 deficiency is a 
common (and commonly unrecognized) disorder, with a 
prevalence of up to 10% in the elderly population7 Vitamin 
Btz deficiency often accompanies atrophic gastritis, and the 
prevalence of atrophic gastritis in the elderly population is 
approximately 3O%.8 Vitamin B12 deficiency may also play a 
role in the osteoporosis that commonly develops following 
gastrectomy and gastric bypass procedures.9,t0 Whether 
treatment with vitamin B12 replacement. either alone or in 
combination with cyclic etidronate, will be as effective a 
treatment for osteoporosis in other patients with vitamin 
B12 deficiency is a question that warrants investigation. 
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